Stay updated on Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    A system-wide notice about a lapse in government funding and a site revision from v3.4.0 to v3.4.1 were added. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-03T23:41:57.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    New Study Documents entries were added, including the Study Protocol PDF and the Statistical Analysis Plan PDF, with corresponding metadata. A glossary toggle was also introduced on the page to aid understanding.
    Difference
    63%
    Check dated 2026-01-27T21:08:46.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-20T15:43:26.000Z thumbnail image
  4. Check
    47 days ago
    Change Detected
    Summary
    The page's location information was reorganized to include a top-level Locations section with Barcelona and Navarre, replacing the previous Barcelona and Navarre Locations entries. The revision version updated to v3.3.3 and the HHS Vulnerability Disclosure link was removed.
    Difference
    0.3%
    Check dated 2025-12-22T00:40:11.000Z thumbnail image
  5. Check
    69 days ago
    Change Detected
    Summary
    Page revision updated from v3.3.1 to v3.3.2.
    Difference
    0.0%
    Check dated 2025-11-30T16:19:29.000Z thumbnail image
  6. Check
    76 days ago
    Change Detected
    Summary
    Publications section now states that publications are automatically filled from PubMed and displays revision: v3.3.1. The previous PubMed-origin wording and the older revision (v3.2.0) have been removed.
    Difference
    0.1%
    Check dated 2025-11-23T14:53:25.000Z thumbnail image

Stay in the know with updates to Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.